Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Two-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CAT 2003 (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Adverse reactions
  • Sponsors Astria Therapeutics; Catabasis Pharmaceuticals

    • Most Recent Events

    • 02 May 2014 Results presented at the National Lipid Association (NLA) Scientific Sessions 2014, according to to a Catabasis media release.
    • 31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 31 Mar 2014 Results will be presented at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14) according to a Catabasis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top